Designer pharmacotherapy for the treatment of cystic fibrosis: Commentary on Zegarra-Moran et al

British Journal of Pharmacology

Volumn 137, Issue 4, 2002, Pages 411-412

  Gray, M A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cystic fibrosis; Mutant CFTR; Pharmacotherapy

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR; CARRIER PROTEIN; GOPC PROTEIN, HUMAN; MEMBRANE PROTEIN;

CHLORIDE TRANSPORT; CYSTIC FIBROSIS; GENE MUTATION; GENE THERAPY; HUMAN; NOTE; PRIORITY JOURNAL; SODIUM TRANSPORT; ANIMAL; DRUG DESIGN; GENETICS; METABOLISM; RAT;

ANIMALS; CARRIER PROTEINS; CYSTIC FIBROSIS; DRUG DESIGN; MEMBRANE PROTEINS; RATS;

EID: 0036800499     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704883     Document Type: Note

References (11)

1. Becq, F., Mettey, Y., Gray, M.A., Galietta, L.J.V., Dormer, R.L., Merten, M., Metaye, T., Chappe, V., Marivingt-Mounir, C., Zegarra-Moran, O., Tarran, R., Bulteau, L., Derand, R., Pereira, M.M.C., McPherson, M.A., Rogier, C., Joffre, M., Argent, B.E., Sarrouilhe, D., Kammouni, W., Figarella, C., Verrier, B., Gola, M. & Vierfond, J.M. (1999). Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J. Biol. Chem., 274, 27415-27425.
2. Derand, R., Bulteau-Pignoux, L., Mettey, Y., Zegarra-Moran, O., Howell, D., Randak, C., Galietta, L.J.V., Cohn, J.A., Norez, C., Romio, L., Vierfrond, J.M., Joffre, M. & Becq, F. (2001). Activation of G551D CFTR channel with MPB-91: Regulation by ATPase activity and phosphorylation. Am. J. Physiol., 281, C1657-C1666.
3. Dormer, R.L., Derand, R., McNeilly, C.N., Mettey, Y., Bulteau-Pignoux, L., Vierfond, J.M., Gray, M.A., Galieta, L.J.V., Morris, M.R., Pereira, M.M.C., Doull, I.J.M., Becq, F. & McPherson, M.A. (2001). Correction of delF508-CFTR activity with benzo[c]quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J. Cell Sci., 114, 4073-4081.
4. Galietta, L.J.V., Springsteel, M.F., Eda, M., Niedzinski, E.J., By, K., Haddadin, M.J., Kurth, M.J., Nantz, M.H. & Verkman, A.S. (2001). Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem., 276, 19723-19728.
5. Howell, D.L., Borchardt, R. & Cohn, J.A. (2000). ATP hydrolysis by a CFTR domain: Pharmacology and effects of G551D mutation. Biochim. Biophys. Res. Comm., 271, 518-525.
6. Illek, B., Fischer, H., Santos, G.F., Widdicombe, J.H., Machen, T.E. & Reenstra, W.W. (1995). cAMP-independent activation of CFTR C1 channels by the tyrosine kinase inhibitor genistein. Am. J. Physiol., 268, C886-C893.
7. Illek, B., Zhang, L., Lewis, N.C., Moss, R.B., Dong, J.-Y. & Fischer, H. (1999). Defective function of the cystic fibrosis- causing missense mutation G551D is recovered by genistein. Am. J. Physiol., 277, C833-C839.
8. Kunzelmann, K. & Mall, M. (2001). Pharmacotherapy of the ion transport defect in cystic fibrosis. Clinical Exp. Pharm. Physiol., 28, 857-867.
9. Schultz, B.D., Singh, A.K., Devor, D.C. & Bridges, R.J. (1999). Pharmacology of CFTR chloride channel activity. Physiol. Revs., 79, S109-S144.
10. Tarran, R., Grubb, B.R., Parsons, D., Picher, M., Hirsh, A.J., Davis, C.W. & Boucher, R.C. (2001). The CF salt controversy: In vivo observations and therapeutic approaches. Mol. Cell., 8, 149-158.
11. Zegarra-Moran, O., Romio, L., Folli, C., Caci, E., Becq, F., Vierfrond, J.M., Mettey, Y., Cabrini, G., Fanen, P. & Galietta, L.J.V. (2002). Correction of G511D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Brit. J. Pharmacol., in press.